Clinical ResearchHeart FailureThe Vascular Marker Soluble Fms-Like Tyrosine Kinase 1 Is Associated With Disease Severity and Adverse Outcomes in Chronic Heart Failure
Key Words
Abbreviations and Acronyms
Cited by (0)
Dr. Ky was supported by the National Institutes of Health (NIH)/Clinical and Translational Science Award KL1 RR024132, NIH K23 HL095661-01, and the Heart Failure Society of America Research Fellowship Award. This work was also supported by NIH HL088577 (Dr. Cappola). Assay support was provided by Abbott Diagnostics. Neither the funding organizations nor Abbott Diagnostics had any role in the design or conduct of the study; collection, management, analysis, or interpretation of the data; or preparation, review, or approval of the manuscript. Dr. Levy has received research support from Thoratec, General Electric, and Heartware; has received honoraria from GlaxoSmithKline and Boehringer Ingelheim; has licensing with the ACC Toolkit, Epocrates, and Seattle Heart Failure Model; has served on the Steering Committee of Amgen and Scios; has served on the Clinical Endpoint Committee of Cardiomems; and has done consulting with stock options for Cardiac Dimensions. Dr. Cappola reports receiving research support from Abbott Diagnostics. Drs. Ky and Cappola are co-inventors on a pending intellectual property application for the use of sFlt-1 as a biomarker in heart failure. All other authors have reported that they have no relationships to disclose.